Interleukin-6-producing paraganglioma as a rare cause of systemic inflammatory response syndrome: a case report
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Pheochromocytomas and paragangliomas (PPGLs) may secrete hormones or bioactive neuropeptides such as interleukin-6 (IL-6), which can mask the clinical manifestations of catecholamine hypersecretion. We report the case of a patient with delayed diagnosis of paraganglioma due to the development of IL-6-mediated systemic inflammatory response syndrome (SIRS). A 58-year-old woman presented with dyspnea and flank pain accompanied by SIRS and acute cardiac, kidney, and liver injuries. A left paravertebral mass was incidentally observed on abdominal computed tomography (CT). Biochemical tests revealed increased 24-hour urinary metanephrine (2.12 mg/day), plasma norepinephrine (1,588 pg/mL), plasma normetanephrine (2.27 nmol/L), and IL-6 (16.5 pg/mL) levels. 18F-fluorodeoxyglucose (FDG) positron emission tomography/CT showed increased uptake of FDG in the left paravertebral mass without metastases. The patient was finally diagnosed with functional paraganglioma crisis. The precipitating factor was unclear, but phendimetrazine tartrate, a norepinephrine-dopamine release drug that the patient regularly took, might have stimulated the paraganglioma. The patient’s body temperature and blood pressure were well controlled after alpha-blocker administration, and the retroperitoneal mass was surgically resected successfully. After surgery, the patient’s inflammatory, cardiac, renal, and hepatic biomarkers and catecholamine levels improved. In conclusion, our report emphasizes the importance of IL-6-producing PPGLs in the differential diagnosis of SIRS.
Abstract
Pheochromocytomas and paragangliomas (PPGLs) may secrete hormones or bioactive neuropeptides such as interleukin-6 (IL-6), which can mask the clinical manifestations of catecholamine hypersecretion. We report the case of a patient with delayed diagnosis of paraganglioma due to the development of IL-6-mediated systemic inflammatory response syndrome (SIRS). A 58-year-old woman presented with dyspnea and flank pain accompanied by SIRS and acute cardiac, kidney, and liver injuries. A left paravertebral mass was incidentally observed on abdominal computed tomography (CT). Biochemical tests revealed increased 24-hour urinary metanephrine (2.12 mg/day), plasma norepinephrine (1,588 pg/mL), plasma normetanephrine (2.27 nmol/L), and IL-6 (16.5 pg/mL) levels. 18F-fluorodeoxyglucose (FDG) positron emission tomography/CT showed increased uptake of FDG in the left paravertebral mass without metastases. The patient was finally diagnosed with functional paraganglioma crisis. The precipitating factor was unclear, but phendimetrazine tartrate, a norepinephrine-dopamine release drug that the patient regularly took, might have stimulated the paraganglioma. The patient’s body temperature and blood pressure were well controlled after alpha-blocker administration, and the retroperitoneal mass was surgically resected successfully. After surgery, the patient’s inflammatory, cardiac, renal, and hepatic biomarkers and catecholamine levels improved. In conclusion, our report emphasizes the importance of IL-6-producing PPGLs in the differential diagnosis of SIRS.
참고문헌 (20)
- crisis, "Clin Endocrinol(Oxf)", 2014, 13~22
- Tanaka T, "IL-6 in inflammation, immunity, and disease", Cold Spring Harb Perspect Biol, 6, pp.a016295~ (2014)
- Akira S, "Biology of multifunctional cytokines : IL 6 and related molecules(IL 1 and TNF)", FASEB J, 4, pp.2860~2867 (1990)
- Carvalho Cunha N, "Interleukin-6 producing pheochromocytoma : a rare cause of systemic inflammatory response syndrome", Case Rep Endocrinol, 2019, pp.7906272~ (2019)
- Meijs AC, "Interleukin-6 producing pheochromocytoma", paraganglioma : case series from a tertiary referral centre for pheochromocytomas and paragangliomas, 2021, pp.44, 2253~2259
- Angelousi A, "Malignant pheochromocytomas", paragangliomas and ectopic hormonal secretion : a case series and review of the literature, 2019, pp.11, 724~
- Cheng X, "Interleukin-6-producing pheochromocytoma as a new reason for fever of unknown origin : a retrospective study", Endocr Pract, 24, pp.507~511 (2018)
- Minetto M, "Interleukin-6 producing pheochromocytoma presenting with acute inflammatory syndrome", J Endocrinol Invest, 26, pp.453~457 (2003)
- Kang JM, "Systemic inflammatory syndrome and hepatic inflammatory cell infiltration caused by an interleukin-6 producing pheochromocytoma", Endocr J, 52, pp.193~198 (2005)
- Yarman S, "Interleukin-6-producing pheochromocytoma presenting with fever of unknown origin", Clinics(Sao Paulo), 66, pp.1843~1845 (2011)
- Martucci VL, "Pheochromocytoma and paraganglioma : diagnosis, genetics, management, and treatment", Curr Probl Cancer, 38, pp.7~41 (2014)
- 김경진, "Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force", Endocrinology and Metabolism, 36(2), pp.322~338 (2021), 대한내분비학회[DOI]
- Nölting S, "Personalized management of pheochromocytoma and paraganglioma", Endocr Rev, 43, pp.199~239 (2022)
- Gimenez-Roqueplo AP, "An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes", Horm Metab Res, 44, pp.328~333 (2012)
- van Hulsteijn LT, "Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers : a systematic review and meta-analysis", J Med Genet, 49, pp.768~776 (2012)
- Benn DE, "Clinical presentation and penetrance of pheochromocytoma", paraganglioma syndromes, 2006, pp.91, 827~836
- Boyd J, "A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position", Eur J Endocrinol, 181, pp.301~309 (2019)
- Shimizu C, "Interleukin-6(IL-6)producing phaeochromocytoma : direct IL-6 suppression by non-steroidal anti-inflammatory drugs", Clin Endocrinol(Oxf), 54, pp.405~410 (2001)
- Fiebich BL, "Effects of NSAIDs on IL-1 beta-induced IL-6 mRNA and protein synthesis in human astrocytoma cells", Neuroreport, 7, pp.1209~1213 (1996)
- Tung D, "Novel anti-inflammatory effects of doxazosin in rodent models of inflammation", Pharmacology, 91, pp.29~34 (2013)